Fresenius Divests Brazilian Sites To EMS Amid Structural Streamlining

The Company Sold A Generic Injectable Manufacturing Plant For An Undisclosed Sum

 
• By Adam Zamecnik
  
Brazil's medicines regulator announces maximum price adjustments permitted in 2025. (Shutterstock)

More from Deals

More from Generics Bulletin